Cost-Effectiveness of Vemurafenib Vs Ipilimumab Plus Dacarbacine in the Treatment of Non-Resectable Metastasic Melanoma with Braf600e Mutation in Colombia
Abstract
Authors
D Rosselli C Castañeda-Cardona JG Bayona YR Díaz Toro SA Saenz Ariza